ClinicalTrials.gg
CompletedNCT01458288Updated Apr 19, 2021Results posted

A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

A Phase 2 interventional study of TG-0054 in Multiple Myeloma, Non-hodgkin's Lymphoma and Hodgkin's Disease, sponsored by GPCR Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-19.

Sponsored by GPCR Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,168 studies in Multiple Myeloma with a site in United States — 273 open to participants now, 501 under way, 66 of them phase 3. Multiple Myeloma · United States.

Enrollment
1,525th of 1,901
12 · median 36
Started
2012
with 96 others
Phase 2
751 of 2,168
74 open now
Registered
904th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,525th largest by enrollment of the 1,901 interventional ones that give a count, is one of 97 that started in 2012, is one of 751 in phase 2, and was the 904th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

273 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

268 more — sign in →

All 273 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

This Phase II study is to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 alone or in combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease.

03

Conditions studied

  • Multiple Myeloma
  • Non-hodgkin's Lymphoma
  • Hodgkin's Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 18 to 75 years of age inclusive;
  • Patients with confirmed pathology diagnosis of MM, NHL or HD;
  • Potential candidate for stem cell transplantation at Investigator's discretion;
  • 4 weeks since last cycle of chemotherapy prior to the study drug administration;
  • Total dose of melphalan received 200 mg in the most recent chemotherapy treatment;
  • (ECOG) performance status of 0 or 1;
  • Recovered from all acute toxic effects of prior chemotherapy at Investigator's discretion;
  • White blood cell (WBC) count 3.0 x 109/L on screening laboratory assessments;
  • 1.5 x 109/L on screening laboratory assessments;
  • count 100 x 109/L on screening laboratory assessments;
  • Serum creatinine 2.2 mg/dL on screening laboratory assessments;
  • (AST), alanine aminotransferase (ALT), and total \< 2 x (ULN) on screening laboratory assessments;
  • Negative for (HIV);
  • Adequate cardiac and pulmonary function to undergo leukapheresis at Investigator's discretion;
  • For females, one of the following criteria must be fulfilled:

    1. At least one year , or
    2. Surgically sterile, or
    3. Willing to use a double-barrier method [intrauterine device (IUD) plus condom, spermicidal gel plus condom] of from study Day 1 until 28 days after the last dose of TG-0054;
  • Males must be willing to use a reliable form of contraception (use of a condom or a partner fulfilling the above criteria) from study Day 1 until 28 days after the last dose of TG-0054;
  • Able to provide the signed .

Exclusion criteria

Exclusion Criteria:

  • Received radiation therapy to the pelvis;
  • Received > 6 cycles of lenalidomide;
  • Evidence of bone marrow involvement of lymphoma in NHL patients;
  • Failed previous stem cell collection [failed to collect 2 x 106 CD34+ cells/kg within 4 leukapheresis sessions after receiving granulocyte colony-stimulating factor (G-CSF)];
  • Patients who have undergone previous stem cell transplantation procedure;
  • Received G-CSF within 2 weeks prior to the study drug administration;
  • History of other cancer within the past 5 years excluding MM, NHL, HD, basal cell or squamous cell carcinoma of the skin;
  • History of other hematologic disorders including bleeding or thromboembolic disease being treated with anti-coagulant;
  • History of poor and uncontrollable cardiovascular or pulmonary disease such as myocardial infarction, cardiac arrhythmias, , stroke or (COPD) patients hospitalized more than two times a year due to underlying disease;
  • Diagnosis of sickle cell anemia or documented sickle cell trait;
  • Patients with proliferative retinopathy;
  • Uncontrollable with MM, NHL or HD, or carcinomatous meningitis, at Investigator's discretion;
  • Any infection required antibiotic treatment or unexplained fever above 38 °C within 3 days prior to dosing;
  • Pregnant or breast-feeding;
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study;
  • Received any other drug within 1 month before entering the study;
  • Received prior treatment with TG-0054 but withdrew early from this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    TG-0054 (3.14 mg/kg)

    TG-0054 (3.14 mg/kg)

    Drug: TG-0054

Interventions

  • DrugBurixaforStudies of BurixaforBurixafor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)

    Also known as: burixafor

06

What researchers measure

Primary outcomes

  1. Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg

    Patients were all with multiple myeloma (MM), Non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD). Number of patients who mobilized the targeted total number of CD34+ cells within a maximum of 4 leukapheresis sessions in study arm 1 and arm 3. Patients in arm 1 followed administration of TG-0054 (3.14 mg/kg) alone and leukapheresis start from study day 1. Patients in arm 3 followed administration of TG-0054 (3.14 mg/kg) combined with granulocyte colony-stimulating factor (G-CSF) and leukapheresis start from study day 8.

    Time frame: 1 week

Secondary outcomes

  1. the Average Number of Leukapheresis Sessions

    To determine the average number of leukapheresis sessions required to collect 2.5 x10\^6 CD34+ cells/kg.

    Time frame: 1 week

  2. Circulating CD34+ Cell Count in Peripheral Blood

    Calculate the median total CD34+ cell counts across all leukapheresis sessions following TG 0054 administration alone and in combination with G-CSF mobilization in order to evaluate the pharmacodynamics (PD) of TG-0054 by determining circulating CD34+ cell counts in peripheral blood.

    Time frame: pre-dose(-2 to 0 h),2, 4 and 6 hr after dosing.

07

Results

Posted Jan 8, 2015

Participant flow

Duration of the Study: This study will consist of a 14-day screening period, a 2- to 11-day treatment period, and a 7-day follow-up period. Number of Patients: Approximately 12 treatment evaluable patients will be enrolled in this study. Study Location: Single site in US.

Participant flow — Overall Study
MilestoneTG-0054 (3.14 mg/kg TG-0054 Administrated Via 15-min IV Infus)
Started12
Completed12
Not completed0

Outcome measures

PrimaryNumber of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg

Patients were all with multiple myeloma (MM), Non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD). Number of patients who mobilized the targeted total number of CD34+ cells within a maximum of 4 leukapheresis sessions in study arm 1 and arm 3. Patients in arm 1 followed administration of TG-0054 (3.14 mg/kg) alone and leukapheresis start from study day 1. Patients in arm 3 followed administration of TG-0054 (3.14 mg/kg) combined with granulocyte colony-stimulating factor (G-CSF) and leukapheresis start from study day 8.

Time frame:
1 week
Reported as:
Number · participants
Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg
participantsTG-0054 (3.14 mg/kg)TG-0054 (3.14 mg/kg)+G-CSF
Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg75
Secondarythe Average Number of Leukapheresis Sessions

To determine the average number of leukapheresis sessions required to collect 2.5 x10\^6 CD34+ cells/kg.

Time frame:
1 week
Reported as:
Mean · number of leukapheresis sessions
the Average Number of Leukapheresis Sessions
number of leukapheresis sessionsTG-0054 (3.14 mg/kg)TG-0054 (3.14 mg/kg)+G-CSF
the Average Number of Leukapheresis Sessions2.0 ± 0.821.4 ± 0.55
SecondaryCirculating CD34+ Cell Count in Peripheral Blood

Calculate the median total CD34+ cell counts across all leukapheresis sessions following TG 0054 administration alone and in combination with G-CSF mobilization in order to evaluate the pharmacodynamics (PD) of TG-0054 by determining circulating CD34+ cell counts in peripheral blood.

Time frame:
pre-dose(-2 to 0 h),2, 4 and 6 hr after dosing.
Reported as:
Median · cells/kg
Circulating CD34+ Cell Count in Peripheral Blood
cells/kgTG-0054 (3.14 mg/kg)TG-0054 (3.14 mg/kg)+G-CSF
Circulating CD34+ Cell Count in Peripheral Blood6000000 (4000000 to 10000000)5000000 (4000000 to 21000000)

Adverse events

Collected over 9 months, from 23-Oct-2012 to 09-Jul-2013. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TG-0054 (3.14 mg/kg Administrated Via 15-min IV Infusion)—0/12 (0%)10/12 (83.3%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventTG-0054 (3.14 mg/kg Administrated Via 15-min IV Infusion)
DiarrhoeaGastrointestinal disorders4/12
Neuropathy peripheralNervous system disorders4/12
Abdominal painGastrointestinal disorders2/12
NauseaGastrointestinal disorders2/12
Paraesthesia oralGastrointestinal disorders2/12
Blood pressure increasedInvestigations2/12
Haemoglobin decreasedInvestigations2/12
Platelet count decreasedInvestigations2/12
ParaesthesiaNervous system disorders2/12
CoughRespiratory, thoracic and mediastinal disorders2/12

Baseline characteristics

Age, Customized
Age, Customized(participants)TG-0054 (3.14 mg/kg Administrated Via 15-min IV Infusion)
18 to 75 years old12
Sex: Female, Male
Sex: Female, Male(Participants)TG-0054 (3.14 mg/kg Administrated Via 15-min IV Infusion)
Female6
Male6
Region of Enrollment
Region of Enrollment(participants)TG-0054 (3.14 mg/kg Administrated Via 15-min IV Infusion)
United States12
08

Study locations

1 site
  • Stony Brook University Hospital
    Stony Brook, New York 11794, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2011
First posted
Oct 24, 2011
Start
Oct 2012
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results first posted
Jan 8, 2015
Last update
Apr 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01458288
Lead sponsor
GPCR Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 24, 2011
Start date
Oct 2012
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Jan 8, 2015
Last update
Apr 19, 2021

Study contacts

Michael W. Schuster, M.D.
principal investigator · Stony Brook University Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Burixafor

Start the discussion